Advancing precision care
Many existing therapies for cancer and rare diseases are non-selective, killing healthy tissue and impacting vital organs at the same time as treating disease. Targeted radiation is intended to seek out cancerous or diseased cells with precision, regardless of where they are in the body.
When the radioactive “payload” uses diagnostic radionuclides, imaging can be used to precisely localise disease and stage a patient’s cancer. When therapeutic isotopes are delivered to the cancerous or diseased cell, the patient is treated in a way that spares most normal healthy tissue and optimises patient outcomes.
Our global footprint
Telix is headquartered in Melbourne, Australia with commercial operations supporting the Americas, Europe Middle East and Africa, and Asia Pacific Regions. We have offices in Australia, Belgium, Japan, Switzerland, and the United States.
Our manufacturing hub in Belgium will deliver significant operational flexibility, R&D capabilities, and support commercial production requirements in Europe.
Disease areas and programs
Telix’s research pipeline aims to address significant unmet medical need in prostate, renal (kidney), brain (glioblastoma), and hematologic cancers (bone marrow conditioning) as well as a range of immunologic and rare diseases.
